Patient information overview
| . | Number . | Total, % . |
|---|---|---|
| Age, y | ||
| <60 | 113 | 48.92 |
| >60 | 118 | 51.08 |
| Sex | ||
| Male | 129 | 55.84 |
| Female | 102 | 44.16 |
| Hemoglobin, g/L | ||
| <120 | 202 | 87.45 |
| >120 | 29 | 12.55 |
| White blood cell count, ×109/L | ||
| <3.5 | 81 | 35.06 |
| 3.5-10.5 | 56 | 24.24 |
| >10.5 | 94 | 40.69 |
| Absolute neutrophil count, ×109/L | ||
| <2 | 156 | 67.53 |
| 2.0-7.5 | 50 | 21.65 |
| >7.5 | 24 | 10.39 |
| Unavailable | 1 | 0.43 |
| Platelet, ×109/L | ||
| <130 | 179 | 77.49 |
| 130-380 | 50 | 21.65 |
| >380 | 229 | 99.13 |
| Mean corpuscular volume, g/L | ||
| <80 | 7 | 3.03 |
| 80-100 | 160 | 69.26 |
| >100 | 64 | 27.71 |
| Red cell distribution width, % | ||
| <11.5 | 0 | 0 |
| 11.5-15.5 | 66 | 28.57 |
| >15.5 | 136 | 58.87 |
| Unavailable | 29 | 12.55 |
| Peripheral blood blasts, % | ||
| <20 | 185 | 80.09 |
| >20 | 46 | 19.91 |
| Lactate dehydrogenase, IU/L | ||
| <100 | 0 | 0 |
| 100-205 | 6 | 2.6 |
| >205 | 73 | 31.6 |
| Unavailable | 152 | 65.8 |
| AML type | ||
| De novo | 215 | 93.07 |
| Secondary to MDS/MPN | 12 | 5.19 |
| t-AML | 4 | 1.73 |
| Bone marrow blasts, % | ||
| <20 | 11 | 4.76 |
| >20 | 204 | 88.31 |
| Normal cytogenetics | ||
| Not present | 125 | 54.11 |
| Present | 105 | 45.45 |
| Cytogenetic risk score | ||
| Good | 21 | 9.09 |
| Intermediate | 149 | 64.5 |
| Poor | 32 | 13.85 |
| Unavailable | 29 | 12.55 |
| ELN risk score | ||
| Unavailable | 2 | 0.87 |
| Not calculated | 28 | 12.12 |
| Good | 84 | 36.36 |
| Intermediate | 57 | 24.68 |
| Poor | 62 | 26.84 |
| Induction therapy | ||
| 7+3 | 231 | 100 |
| Other | 0 | 0 |
| Response | ||
| CR | 177 | 76.62 |
| NR | 54 | 23.37 |
| MRD | ||
| Negative | 146 | 63.2 |
| Positive | 52 | 22.51 |
| Unavailable | 33 | 14.29 |
| Relapse | ||
| No relapse | 149 | 64.50 |
| Relapse | 82 | 35.50 |
| Outcomes | ||
| CR_MRD+ | 37 | 16.02 |
| CR_MRD– | 126 | 54.55 |
| NR_MRD+ | 15 | 6.49 |
| NR_MRD– | 20 | 8.66 |
| CR_MRD_unknown | 13 | 5.63 |
| NR_MRD_unknown | 19 | 8.23 |
| CR_relapse | 61 | 26.41 |
| CR_norelapse | 116 | 50.22 |
| NR_relapse | 21 | 9.09 |
| NR_norelapse | 33 | 14.29 |
| . | Number . | Total, % . |
|---|---|---|
| Age, y | ||
| <60 | 113 | 48.92 |
| >60 | 118 | 51.08 |
| Sex | ||
| Male | 129 | 55.84 |
| Female | 102 | 44.16 |
| Hemoglobin, g/L | ||
| <120 | 202 | 87.45 |
| >120 | 29 | 12.55 |
| White blood cell count, ×109/L | ||
| <3.5 | 81 | 35.06 |
| 3.5-10.5 | 56 | 24.24 |
| >10.5 | 94 | 40.69 |
| Absolute neutrophil count, ×109/L | ||
| <2 | 156 | 67.53 |
| 2.0-7.5 | 50 | 21.65 |
| >7.5 | 24 | 10.39 |
| Unavailable | 1 | 0.43 |
| Platelet, ×109/L | ||
| <130 | 179 | 77.49 |
| 130-380 | 50 | 21.65 |
| >380 | 229 | 99.13 |
| Mean corpuscular volume, g/L | ||
| <80 | 7 | 3.03 |
| 80-100 | 160 | 69.26 |
| >100 | 64 | 27.71 |
| Red cell distribution width, % | ||
| <11.5 | 0 | 0 |
| 11.5-15.5 | 66 | 28.57 |
| >15.5 | 136 | 58.87 |
| Unavailable | 29 | 12.55 |
| Peripheral blood blasts, % | ||
| <20 | 185 | 80.09 |
| >20 | 46 | 19.91 |
| Lactate dehydrogenase, IU/L | ||
| <100 | 0 | 0 |
| 100-205 | 6 | 2.6 |
| >205 | 73 | 31.6 |
| Unavailable | 152 | 65.8 |
| AML type | ||
| De novo | 215 | 93.07 |
| Secondary to MDS/MPN | 12 | 5.19 |
| t-AML | 4 | 1.73 |
| Bone marrow blasts, % | ||
| <20 | 11 | 4.76 |
| >20 | 204 | 88.31 |
| Normal cytogenetics | ||
| Not present | 125 | 54.11 |
| Present | 105 | 45.45 |
| Cytogenetic risk score | ||
| Good | 21 | 9.09 |
| Intermediate | 149 | 64.5 |
| Poor | 32 | 13.85 |
| Unavailable | 29 | 12.55 |
| ELN risk score | ||
| Unavailable | 2 | 0.87 |
| Not calculated | 28 | 12.12 |
| Good | 84 | 36.36 |
| Intermediate | 57 | 24.68 |
| Poor | 62 | 26.84 |
| Induction therapy | ||
| 7+3 | 231 | 100 |
| Other | 0 | 0 |
| Response | ||
| CR | 177 | 76.62 |
| NR | 54 | 23.37 |
| MRD | ||
| Negative | 146 | 63.2 |
| Positive | 52 | 22.51 |
| Unavailable | 33 | 14.29 |
| Relapse | ||
| No relapse | 149 | 64.50 |
| Relapse | 82 | 35.50 |
| Outcomes | ||
| CR_MRD+ | 37 | 16.02 |
| CR_MRD– | 126 | 54.55 |
| NR_MRD+ | 15 | 6.49 |
| NR_MRD– | 20 | 8.66 |
| CR_MRD_unknown | 13 | 5.63 |
| NR_MRD_unknown | 19 | 8.23 |
| CR_relapse | 61 | 26.41 |
| CR_norelapse | 116 | 50.22 |
| NR_relapse | 21 | 9.09 |
| NR_norelapse | 33 | 14.29 |
ELN risk scores were assigned at the time of diagnosis and reflect guidelines established in 2017. Cytogenic risk score is a criterion that solely considers the cytogenic status of the patient, and this score was collected independently of ELN 2017 risk score for our patients.
CR, complete response; ELN, European Leukemia Network; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MRD, minimal residual disease; NR, no response; t-AML, therapy related AML.